title: Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
abstract: OBJECTIVE
  To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP.
  
  
  METHODS
  This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4).
  
  
  RESULTS
  A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Twenty-nine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4 cell count above 250 cells/mul or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected as compared to those taking other ART regardless of prior exposure history.
  
  
  CONCLUSIONS
  We did not observe an increased risk of hepatotoxicity among HIV-infected pregnant women on NVP versus other ART, including women who were ART naive.
authors.affiliation: Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. douyang@northshore.org
authors.forename: David W
authors.initials: DW
authors.lastname: Ouyang
authors.forename: Susan B
authors.initials: SB
authors.lastname: Brogly
authors.forename: Ming
authors.initials: M
authors.lastname: Lu
authors.forename: David E
authors.initials: DE
authors.lastname: Shapiro
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Hershow
authors.forename: Audrey L
authors.initials: AL
authors.lastname: French
authors.forename: Robert M
authors.initials: RM
authors.lastname: Leighty
authors.forename: Bruce
authors.initials: B
authors.lastname: Thompson
authors.forename: Ruth E
authors.initials: RE
authors.lastname: Tuomala
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D056486:Chemical and Drug Induced Liver Injury / Q000517:prevention & control*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012044:Regression Analysis
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine